Investors & Media Press Releases Investor Relations Overview Corporate Governance Press Releases & Statements Events & Presentations SEC Filings Annuals and Proxies Investor FAQs Financials & Filings Stock Information Analyst Coverage Email Alerts Subscription Notice of Pendency of Settlement of Action Press Releases Items Per Page 102550 Year None2023202220212020201920182017 Date Title View Toggle Summary November 8, 2023 Sage Therapeutics to Present at Upcoming November Investor Conferences Sage Therapeutics to Present at Upcoming November Investor Conferences Toggle Summary November 7, 2023 Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Toggle Summary October 24, 2023 Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 Toggle Summary October 18, 2023 Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease Toggle Summary September 6, 2023 Sage Therapeutics to Present at Upcoming September Investor Conferences Sage Therapeutics to Present at Upcoming September Investor Conferences Toggle Summary August 31, 2023 Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement Toggle Summary August 7, 2023 Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Toggle Summary August 4, 2023 Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023 Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023 Toggle Summary August 4, 2023 FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder Toggle Summary June 5, 2023 Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference Pagination Current page 1 Page 2 Page 3 Next page Next Last page Last Displaying 1 - 10 of 23
Press Releases Items Per Page 102550 Year None2023202220212020201920182017 Date Title View Toggle Summary November 8, 2023 Sage Therapeutics to Present at Upcoming November Investor Conferences Sage Therapeutics to Present at Upcoming November Investor Conferences Toggle Summary November 7, 2023 Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Toggle Summary October 24, 2023 Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 Toggle Summary October 18, 2023 Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease Toggle Summary September 6, 2023 Sage Therapeutics to Present at Upcoming September Investor Conferences Sage Therapeutics to Present at Upcoming September Investor Conferences Toggle Summary August 31, 2023 Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement Toggle Summary August 7, 2023 Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Toggle Summary August 4, 2023 Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023 Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023 Toggle Summary August 4, 2023 FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder Toggle Summary June 5, 2023 Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference Pagination Current page 1 Page 2 Page 3 Next page Next Last page Last Displaying 1 - 10 of 23
